NASDAQ:SNGX
Soligenix, Inc Stock News
$0.405
+0 (+0%)
At Close: May 03, 2024
Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and Pfizer
08:30am, Wednesday, 09'th Dec 2020
New York, New York--(Newsfile Corp. - December 9, 2020) - The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 mill
Soligenix: One Approvable Drug And Another With Phase 3 Read Out Soon - $55M Valuation Won't Last
12:38am, Monday, 26'th Oct 2020
Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 for oral
